Lifebit CloudOS operates as a managed informatics platform that removes the industry barrier of vast amounts of inaccessible distributed omics data, enables federated bioinformatics analysis and machine learning
LONDON, UK – Nov 07, 2019 – Lifebit Biotech, a leading innovator in bioinformatics and cognitive software solutions, announced today the general release of Lifebit CloudOS. The fully federated, cloud-native system is designed for companies in the pharmaceutical, drug discovery, direct-to-consumer genetics, healthcare, and population genomics industries. Some of the largest life sciences organisations have deployed Lifebit’s operating system to accelerate discoveries. Lifebit CloudOS is the culmination of 2 years of development and is the successor to the beta release Lifebit Deploit.
Lifebit CloudOS solves the major barrier faced by the genomics sector: data is often siloed and distributed, inaccessible for multiple parties to analyse. Without the ability to perform analyses across this distributed data the industry is stalled, impeding critical progress in precision medicine and life sciences.
“Until now, the complex and distributed nature of omics analysis has presented major obstacles for companies and research organisations alike,” explained Dr Maria Chatzou Dunford, Lifebit CEO. “With Lifebit CloudOS, we removed those obstacles. Because it is completely agnostic to the customer’s HPC and cloud infrastructure, workflows and data, Lifebit CloudOS is unlike any other genomics platforms in that it sits natively on one’s cloud/HPC and brings computation to the data instead of the other way around. This is a game-changer for organisations in genomics fields where data is too big to move and security and compliance are absolutely paramount.”
Lifebit CloudOS brings a radically new approach to bioinformatics. It works as a managed service of one’s cloud or HPC, ensuring analysis and machine learning runs over distributed data where that data resides. The system deploys and automates analysis, producing quick insights. It also remedies the shortages of highly-trained bioinformaticians required to generate insights from sequencing data. With Lifebit CloudOS anyone can run analyses at scale, access best-in-class pipelines, and easily manage complex data and resources all at one web page.
Dr Pablo Prieto Barja, Lifebit CTO, said, “Scaling genetic data analyses for millions of individuals’ data is a critical challenge for life sciences companies. Lifebit CloudOS eliminates this barrier via cloud/HPC abstraction in a unified, federated way. Our clients are able to scale quickly while drastically reducing costs and speeding time to results, affording them tremendous competitive advantages. We are absolutely thrilled to announce the general release of Lifebit CloudOS.”
Lifebit CloudOS is free to trial
Lifebit CloudOS Key Features
- Plug & play – simplifies and maximises access to data
- Federated analysis & Machine Learning – facilitates exploration of data and allows analyses of these data in-situ
- Comprehensive dashboards and automated processes
- Best-in-class accelerated analysis pipelines
- Integration capabilities of the various datasets allows researchers to more easily understand disease mechanisms and the links between phenotypic, genetic, imaging and other -omics
- Cost reductions – leverage spot instances intelligently through the cloud
- Bioinformatics-as-a-Service turns raw data into results via intuitive API
Leading life sciences organisations are accelerating their research and discoveries with Lifebit. Lifebit CloudOS is the federated, integrated solution for fully FAIR omics and biomedical analysis, allowing anyone to streamline and scale analyses faster, cheaper, and securely in their own data environments. Lifebit AI-Engine has deep-learned the biology behind drug response and is helping pharmaceutical companies repurpose drugs, validate targets and optimise vaccines by reasoning about omics data like humans would. Headquartered in London, UK, Lifebit’s ecosystem of employees, partners, and customers spans 15 countries.
Press contact: firstname.lastname@example.org